Cevostamab

Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on T cells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells[1][2].

Product Specifications

CAS Number

[2249888-53-5]

Product Name Alternative

BFCR 4350A; RG 6160; RO 7187797

UNSPSC

12352203

Target

CD3

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/cevostamab.html

Purity

97.00

Solubility

10 mM in DMSO

Smiles

[Cevostamab]

Molecular Weight

(146.19 kDa)

References & Citations

[1]Li J, et al. Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing. Cancer Cell. 2017 Mar 13;31 (3) :383-395. |[2]Hosny M, et al. Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma. J Clin Med. 2021 Oct 6;10 (19) :4593.